LC
MDGL icon

L1 Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

L1 Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50,230
Closed -$11.6M – 14
2023
Q4 		$11.6M Buy
50,230
+1,761
+4% +$308K 1.09% 12
2023
Q3 		$7.08M Buy
48,469
+2,730
+6% +$514K 0.6% 12
2023
Q2 		$10.6M Buy
+45,739
New +$12.4M 1.27% 13
2023
Q1 		– Sell
-133,312
Closed -$38.7M – 13
2022
Q4 		$38.7M Sell
133,312
-27,851
-17% -$2.72M 5.97% 8
2022
Q3 		$10.5M Sell
161,163
-6,840
-4% -$475K 2.05% 10
2022
Q2 		$10.6M Sell
168,003
-47,313
-22% -$3.48M 2.06% 11
2022
Q1 		$15.1M Buy
215,316
+47,655
+28% +$4.02M 1.83% 10
2021
Q4 		$14.2M Buy
167,661
+2,801
+2% +$230K 1.64% 13
2021
Q3 		$13.2M Hold
164,860
– – 1.64% 13
2021
Q2 		$16.1M Buy
164,860
+52,256
+46% +$6.19M 3.32% 9
2021
Q1 		$13.2M Sell
112,604
-860
-0.8% -$100K 3.31% 9
2020
Q4 		$12.6M Sell
113,464
-1,197
-1% -$146K 2.35% 13
2020
Q3 		$13.6M Sell
114,661
-2,670
-2% -$290K 4.37% 7
2020
Q2 		$13.3M Buy
+117,331
New +$11.5M 4.54% 8

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

L1 Capital's MDGL Position: Q1 2024 in Review

L1 Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2024, closing a stake of 50,230 shares — an estimated $11.6M sold.

L1 Capital first reported a position in MDGL in Q2 2020 and held it in 14 quarters. The position peaked at $38.7M in Q4 2022. 268 funds tracked by Wall St. Rank hold MDGL as of Q1 2024.

  • L1 Capital reported no remaining Madrigal Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • L1 Capital sold 50,230 Madrigal Pharmaceuticals shares in Q1 2024, an estimated $11.6M.
  • L1 Capital first reported a position in Madrigal Pharmaceuticals in Q2 2020 and held it in 14 quarters.
  • L1 Capital's Madrigal Pharmaceuticals position peaked at $38.7M in Q4 2022.
  • 268 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2024.

Based on L1 Capital's 13F filing for Q1 2024, filed 15 May 2024.